References
- BarrecaALasorsaERieraLEuropean T-Cell Lymphoma Study GroupAnaplastic lymphoma kinase in human cancerJ Mol Endocrinol2011471R11R2321502284
- SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature2007448715356156617625570
- WongDWLeungELSoKKUniversity of Hong Kong Lung Cancer Study GroupThe EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRASCancer200911581723173319170230
- ShawATSolomonBTargeting anaplastic lymphoma kinase in lung cancerClin Cancer Res20111782081208621288922
- Xalkori®New York, NYPfizer Labs, Pfizer Inc.; FDA-approved prescribing information; LAB-0441-702015 Available from: http://labeling.pfizer.com/showlabeling.aspx?id=676Accessed February 25, 2016
- ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med2013368252385239423724913
- CamidgeDRBangYJKwakELActivity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 studyLancet Oncol201213101011101922954507
- KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged lung cancersSci Transl Med20124120120ra17
- DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
- LiNMichellysPYKimSActivity of a potent and selective phase I ALK inhibitor LDK378 in naive and crizotinib-resistant preclinical tumor modelsPoster presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNovember 12–16 2011San Francisco, CA Abstract B232
- ShawATKimDWMehraRCeritinib in ALK-rearranged non-small-cell lung cancerN Engl J Med2014370131189119724670165
- FelipEKimDMehraREfficacy and safety of ceritinib in patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of ASCEND-1Poster presented at: European Society for Medical Oncology CongressSeptember 26–30 2014Madrid, Spain Abstract 1295P
- ShawATFelipEVansteenkisteJFEvaluation of ceritinib-treated patients (pts) with anaplastic lymphoma kinase rearranged (ALK+) non-small cell lung cancer (NSCLC) and brain metastases in the ASCEND-1 studyPoster presented at: European Society for Medical Oncology CongressSeptember 26–30 2014Madrid, Spain Abstract 1293P
- Novartis Pharmaceuticals Corporation: Zykadia™FDA-approved prescribing information; T2015-114/T2015-1152015 Available from: http://www.pharma.us.novartis.com/product/pi/pdf/zykadia.pdfAccessed February 10, 2016
- WeickhardtAJScheierBBurkeJMLocal ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancerJ Thorac Oncol20127121807181423154552
- ShawATYeapBYSolomonBJEffect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisLancet Oncol201112111004101221933749
- CalifanoRTariqNComptonSExpert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UKDrugs201575121335134826187773
- PartridgeAHAvornJWangPSWinerEPAdherence to therapy with oral antineoplastic agentsJ Natl Cancer Inst200294965266111983753